These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 10827369

  • 1. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
    Topol EJ, Easton JD, Amarenco P, Califf R, Harrington R, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Willerson JT, Chan R, Samuels R, Ilson B, Granett J.
    Am Heart J; 2000 Jun; 139(6):927-33. PubMed ID: 10827369
    [Abstract] [Full Text] [Related]

  • 2. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
    Liu F, Craft RM, Morris SA, Carroll RC.
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2673-87. PubMed ID: 11060829
    [Abstract] [Full Text] [Related]

  • 3. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
    Newby LK.
    Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
    [Abstract] [Full Text] [Related]

  • 4. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
    Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT, Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators.
    Circulation; 2003 Jul 29; 108(4):399-406. PubMed ID: 12874182
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E.
    Circulation; 1998 Feb 03; 97(4):340-9. PubMed ID: 9468207
    [Abstract] [Full Text] [Related]

  • 6. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
    Harrington RA, Armstrong PW, Graffagnino C, Van De Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol EJ.
    Circulation; 2000 Aug 15; 102(7):728-35. PubMed ID: 10942739
    [Abstract] [Full Text] [Related]

  • 7. Role of antiplatelet drugs in the prevention of cardiovascular events.
    Tendera M, Wojakowski W.
    Thromb Res; 2003 Jun 15; 110(5-6):355-9. PubMed ID: 14592562
    [Abstract] [Full Text] [Related]

  • 8. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.
    Circulation; 1999 Apr 20; 99(15):1951-8. PubMed ID: 10208997
    [Abstract] [Full Text] [Related]

  • 9. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA, Donovan JL, Gandhi PJ, Volturo GA.
    Vasc Health Risk Manag; 2006 Apr 20; 2(1):39-48. PubMed ID: 17319468
    [Abstract] [Full Text] [Related]

  • 10. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, Simoons ML, Harrington RA, Topol EJ, Lincoff AM, Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
    Circulation; 2001 Dec 04; 104(23):2772-7. PubMed ID: 11733393
    [Abstract] [Full Text] [Related]

  • 11. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ.
    Am J Cardiol; 1998 Jul 01; 82(1):7-12. PubMed ID: 9671000
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke.
    Lapchak PA, Araujo DM.
    Am J Cardiovasc Drugs; 2003 Jul 01; 3(2):87-94. PubMed ID: 14727935
    [Abstract] [Full Text] [Related]

  • 13. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
    Mould D, Chapelsky M, Aluri J, Swagzdis J, Samuels R, Granett J.
    Clin Pharmacol Ther; 2001 Apr 01; 69(4):210-22. PubMed ID: 11309549
    [Abstract] [Full Text] [Related]

  • 14. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development.
    Verstraete M.
    Circulation; 2000 Feb 15; 101(6):E76-80. PubMed ID: 10673265
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
    Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ.
    Circulation; 1998 Sep 29; 98(13):1268-78. PubMed ID: 9751674
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.
    N Engl J Med; 1998 May 21; 338(21):1488-97. PubMed ID: 9599103
    [Abstract] [Full Text] [Related]

  • 17. Clinical pharmacology of eptifibatide.
    Phillips DR, Scarborough RM.
    Am J Cardiol; 1997 Aug 18; 80(4A):11B-20B. PubMed ID: 9291241
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD.
    J Am Coll Cardiol; 2009 Aug 18; 54(8):678-85. PubMed ID: 19679245
    [Abstract] [Full Text] [Related]

  • 19. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, Gibson CM, Tolleson TR, O'Shea JC, Tcheng JE, ESPRIT Investigators.
    Catheter Cardiovasc Interv; 2007 Jul 01; 70(1):43-50. PubMed ID: 17203469
    [Abstract] [Full Text] [Related]

  • 20. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ, REPLACE-2 Investigators.
    J Am Coll Cardiol; 2004 Sep 15; 44(6):1194-9. PubMed ID: 15364319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.